GB-AF-004

GB-AF-004 is a preclinical-stage therapeutic candidate being developed by GAT Biosciences for the treatment of Inflammatory Bowel Disease (IBD). It is designed as an orally administered agent that targets and neutralizes Tumor Necrosis Factor (TNF), a key pro-inflammatory cytokine central to the pathogenesis of chronic inflammatory conditions like Crohn's disease and ulcerative colitis. While traditional TNF inhibitors are typically administered via injection or infusion, GB-AF-004 is engineered for oral delivery, which may improve patient convenience and potentially localize the drug's therapeutic effect within the gastrointestinal tract. The program is currently in the preclinical phase, involving both in vitro and in vivo studies.